Daewoong Pharmaceutical Expands Nabota Launch to Ecuador, Broadening Latin American Reach
Daewoong Pharmaceutical has launched its botulinum toxin brand, Nabota, in Ecuador, marking its entry into 13 of 20 Latin American countries. The expansion follows its introduction in Panama in 2015 and includes plans to establish Nabota as a premium product through medical training and distribution strategies. The symposium was attended by numerous industry professionals, with positive feedback from key opinion leaders on the product’s high purity and efficacy.
Daewoong Pharmaceutical announced the launch of its botulinum toxin brand, Nabota, in Ecuador on March 7, further solidifying its position in the Latin American market. The company conducted launch symposiums in Guayaquil and Quito on March 27 and 28, respectively. This event marks Nabota’s entry into 13 of the 20 Latin American countries.
Having began its expansion in Panama in 2015, Nabota has established itself in major markets, including Brazil, Argentina, Chile, and Peru. Notably, Daewoong recently signed a significant export contract valued at 180 billion KRW with Brazilian partner Moksha8, expanding the collaboration by approximately tenfold.
In Ecuador, Daewoong intends to position Nabota as a premium product by promoting its quality and sales expertise recognized in regions such as the U.S., Europe, Brazil, and Thailand. The strategy includes developing reliable distribution channels, offering medical training, and instituting reward programs to cultivate trust and long-term relationships with local medical professionals.
The launch symposium witnessed attendance from over 240 professionals specializing in aesthetic and plastic surgery. Renowned key opinion leaders in the plastic surgery field conducted various educational programs related to Nabota, skin boosters, and hyaluronic acid fillers.
Jacqueline Barreto Rodrigues, a Brazilian plastic surgeon, commended Nabota, highlighting that its “purity level of over 98% minimizes impurities, resulting in lower tolerance levels” and allows for more predictable treatment outcomes.
Daewoong’s botulinum toxin is produced with the patented HI-PURE™ Technology and low-pressure drying processes, achieving over 98% purity in 900 kDa complexes, known for delivering swift and precise results. In 2019, it became the first ready botulinum toxin in Asia to receive FDA approval, bolstering its competitive reputation.
Additionally, Daewoong’s botulinum toxin has secured approvals from revered authorities, including the FDA, EMA, and Health Canada, expanding its global presence through partnerships in over 80 nations.
Yoon Jun-soo, head of Daewoong Pharmaceutical’s Nabota division, remarked on the company’s ambition to “rapidly expand our market presence in Ecuador” by leveraging their successes in Brazil and their high-quality standards. He emphasized their goals to expand treatment indications and enter the public procurement market, aiming for significant revenue growth.
In conclusion, Daewoong Pharmaceutical has successfully launched Nabota in Ecuador, marking a significant milestone in its Latin American expansion. With a focus on establishing Nabota as a premium product, and leveraging a comprehensive marketing and training strategy, the company aims to strengthen its footprint in the region. The endorsements from medical professionals, along with Nabota’s proven quality, position it favorably in the competitive market.
Original Source: www.koreaittimes.com
